Primary endpoint: progression-free survival

In the primary analysis ITT population, at a median follow-up of 20.4 months, an mPFS of 20.5 months was achieved in
the KISQALI + fulvestrant arm vs 12.8 months in the placebo + fulvestrant arm; HR=0.59; 95% CI: 0.48–0.73; p<0.001.1

Graph

Adapted from Slamon DJ, et al. 2018.1

CI, confidence interval; HR, hazard ratio; ITT, intention-to-treat; mPFS, median progression-free survival.